Bank of New York Mellon Corp increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.0% during the second quarter, Holdings Channel reports. The institutional investor owned 3,349,821 shares of the biopharmaceutical company’s stock after buying an additional 64,800 shares during the period. Bank of New York Mellon Corp’s holdings in Alexion Pharmaceuticals were worth $407,573,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. raised its stake in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after buying an additional 433,293 shares in the last quarter. State Street Corp raised its stake in shares of Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock valued at $745,579,000 after buying an additional 454,069 shares in the last quarter. 90.74% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 136.55 on Thursday. The stock has a 50 day moving average price of $130.29 and a 200-day moving average price of $123.01. The firm has a market capitalization of $30.48 billion, a PE ratio of 59.22 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the previous year, the business earned $1.13 EPS. The company’s revenue was up 21.1% compared to the same quarter last year. Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Position Boosted by Bank of New York Mellon Corp” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/17/alexion-pharmaceuticals-inc-alxn-position-boosted-by-bank-of-new-york-mellon-corp.html.

ALXN has been the topic of a number of recent analyst reports. Barclays PLC reissued an “overweight” rating and issued a $155.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. UBS AG reaffirmed a “buy” rating and set a $142.00 price target (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. Deutsche Bank AG cut their price target on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Finally, Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and set a $176.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Five equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $156.13.

In other news, CEO Ludwig Hantson acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the purchase, the chief executive officer now owns 38,725 shares in the company, valued at $4,519,982. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders bought a total of 2,019,734 shares of company stock worth $235,606,846 in the last 90 days. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.